Skip to content

S. 2362 · 118th Congress (2023–2025)

Drug Shortage Prevention Act of 2023

This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand, export restriction, or other circumstance that may result in a shortage of certain critical drugs.

Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies.

The bill requires drug manufacturers to also notify the FDA if there is an increased demand, export restriction, or other circumstance that may result in a meaningful shortfall or delay in meeting the demand for such drugs. Manufacturers must notify the FDA as soon as possible but no later than 10 days after the onset of the relevant circumstance. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs.

Drug manufacturers must also report twice a year (rather than annually) information on the quantities of drugs produced; manufacturers must also provide the names of the suppliers of corresponding active ingredients.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.

Expired in Senate committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to committee

This bill’s path

This is S. 2362’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Sen. Amy Klobuchar (D-MN)
Cosponsors
6 cosponsors

4 original · 2 later

2 R · 4 D

  1. Sen. Susan M. Collins (R-ME)· Original · Jul 18, 2023
  2. Sen. Lisa Murkowski (R-AK)· Original · Jul 18, 2023
  3. Sen. Tina Smith (D-MN)· Original · Jul 18, 2023
  4. Sen. Elizabeth Warren (D-MA)· Original · Jul 18, 2023
  5. Sen. Gary C. Peters (D-MI)· Later · Dec 18, 2024
  6. Sen. Ron Wyden (D-OR)· Later · Dec 18, 2024
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources
  3. Expired

    Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Jul 18, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Drug Shortage Prevention Act of 2023

    Display title, Short title · Introduced in Senate

  2. A bill to amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical drugs of increased demand, and for other purposes.

    Official title · Introduced in Senate